-
1.发明公开Use of LCK inhibitors for treatment of immunologic diseases 审中-公开Verwendung von LCK-Hemmern zur Behandlung von Immunerkrankungen
公开(公告)号：EP2281561A2
公开(公告)日：2011-02-09
申请号：EP10184940.4
申请日：2003-08-11
发明人： Roth, Gerald Jürgen , Hauptmann, Rudolf , Hilberg, Frank , Colbatzky, Florian , Ernst, Steffen , Heckel, Armin , Stefanic, Martin, Friedrich , Walter, Rainer
IPC分类号： A61K31/404 , A61K31/454 , A61K31/517 , A61K45/06 , A61P37/00 , A61P37/06 , A61P29/00 , A61P1/00 , A61P3/10 , A61P17/06 , A61P11/06 , A61P25/00
CPC分类号： A61K45/06 , A61K31/404 , A61K31/454 , A61K31/517 , A61K2300/00
摘要： The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
摘要翻译： 本发明涉及一种治疗免疫学疾病或病理状态的方法，该方法使用已知的用于肿瘤学治疗的激酶抑制剂的某些Lck抑制剂，任选地与一种或多种选自NSAID，类固醇，DMARD，免疫抑制剂， 生物反应调节剂和抗感染剂，包含所述Lck抑制剂与所述其它药物的药物组合物，以及使用Lck抑制剂制备用于治疗免疫学疾病或涉及免疫组分的病理状况的药物组合物。
-
公开(公告)号：EP2281561A3
公开(公告)日：2012-05-09
申请号：EP10184940.4
申请日：2003-08-11
发明人： Roth, Gerald Jürgen , Hauptmann, Rudolf , Hilberg, Frank , Colbatzky, Florian , Ernst, Steffen , Heckel, Armin , Stefanic, Martin, Friedrich , Walter, Rainer
IPC分类号： A61K31/404 , A61K31/454 , A61K31/517 , A61K45/06 , A61P37/00 , A61P37/06 , A61P29/00 , A61P1/00 , A61P3/10 , A61P17/06 , A61P11/06 , A61P25/00
CPC分类号： A61K45/06 , A61K31/404 , A61K31/454 , A61K31/517 , A61K2300/00
摘要： The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
-
搜索结果
2 条记录 (耗时 0.009 秒)
